Albany Molecular Research Inc
AMRI
AMRI was delisted on the 31st of August, 2017.
137 hedge funds and large institutions have $506M invested in Albany Molecular Research Inc in 2016 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 47 increasing their positions, 49 reducing their positions, and 16 closing their positions.
28% more capital invested
Capital invested by funds: $394M → $506M (+$112M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 49
4% less funds holding
Funds holding: 142 → 137 (-5)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
98% less call options, than puts
Call options by funds: $1.41M | Put options by funds: $79.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
American Capital Management
New York
|
+$20.3M |
| 2 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$6.72M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$6.13M |
| 4 |
JP Morgan Chase
New York
|
+$3.94M |
| 5 |
PIP
Permian Investment Partners
Dallas,
Texas
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$16.1M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.03M |
| 3 |
Morgan Stanley
New York
|
-$2.19M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$1.94M |
| 5 |
FSA
Franklin Street Advisors
Chapel Hill,
North Carolina
|
-$1.14M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$1K | -84 | Closed |
|
|
GT
152
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$1.19K | -80 | -82% |
|
AMRI Hedge Fund Activity: Q3 2016 in Review
137 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q3 2016, worth a combined $506M — up 28% from $394M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AMRI and 11 opened new positions — a net loss of 5 holders — while 49 trimmed existing stakes and 47 added.
The largest buyer was American Capital Management, opening a new position worth an estimated $20.3M. The largest seller was Wellington Management Group, exiting entirely with an estimated $16.1M sold.
- 137 institutional investors held Albany Molecular Research Inc (AMRI) as of Q3 2016, down from 142 in Q2 2016.
- Funds reported $506M of Albany Molecular Research Inc stock for Q3 2016, up 28% quarter-over-quarter.
- 11 funds opened new Albany Molecular Research Inc positions in Q3 2016 and 16 closed out, a net change of -5 holders.
- The largest Albany Molecular Research Inc buyer in Q3 2016 was American Capital Management, an estimated $20.3M added.
- The largest Albany Molecular Research Inc seller in Q3 2016 was Wellington Management Group, an estimated $16.1M sold.
Based on aggregated 13F filings for Q3 2016.